1Zhao Q,Shentu J,Xu N,et al.Phase Ⅰ study of icotinb hydrochloride(BPI-2009H),an oral EGFR tyrosine kinase inhibitor,in patients with advanced NSCLC and other solid tumors[J].Lung Cancer,2011,73 (2):195-202.
2Shi Y,Zhang L,Liu X,et al.Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer(ICOGEN):a randomised,double-blind phase 3 non-inferiority trial[J].Lancet Oncol,2013,14(10):953-961.
